Thursday, April 27, 2017

Harvest Gold Initiates Program To Establish Drill Targets At Tibiti Project In Suriname



from Harvest Gold Corporation Press Releases http://www.harvestgoldcorp.com/News-Release/News-Release-Details/2017/Harvest-Gold-Initiates-Program-To-Establish-Drill-Targets-At-Tibiti-Project-In-Suriname/default.aspx

Avrupa Closes Financing and Options Portuguese Property

Source: The Gold Report   04/27/2017

Avrupa Minerals, a prospect generator active in Europe, has closed a financing and announced that it has optioned the Alvito project in southern Portugal.

Avrupa Minerals Ltd. (AVU:TSX.V, FWB:8AM) announced on April 20 that it had closed a financing via a private placement, raising $225,000 through issuing 2.5 million common shares at $0.09 per share. In an April 11 announcement, the company noted that the proceeds of the offering "will be used for exploration and operations in Kosovo, Portugal, Vancouver and for general and administration costs."

Paul Kuhn, Avrupa's president & CEO, commented on April 11 that "with our new partner in Portugal funding the Alvito IOCG exploration, and our partner in Kosovo funding a large drill program at the Slivovo gold project, our costs in those locations are low. These new funds will cover costs to advance our other key projects."

The Alvito iron oxide-copper-gold (IOCG) project in southern Portugal was optioned to Australia-based OZ Exploration Pty. Ltd. (OZE), a subsidiary of OZ Minerals Ltd. (OZL:ASX), in an agreement announced on April 10. According to Avrupa, "the agreement allows for OZE to earn up to a total 75% interest in the project by spending AUS $4,000,000 over approximately 2.5 years."

CEO Kuhn noted, "The OZ Minerals exploration team has significant IOCG exploration experience around the world. This is Avrupa's first IOCG target in Portugal, and we look forward to quickly moving the program ahead."

With previous partners, Avrupa developed a central target area of the Alvito project. According to the company, "Exploration work led to the discovery of mineralized stratigraphy beneath 3-10 meters of soil cover through a 29-hole, top-of-bedrock, drilling program completed during 2015."

A new exploration program on Alvito is expected to commence this month. The company states that the program will include "geological mapping, surface sampling, geophysics, further targeted top-of-basement sampling, and a drilling program."

Avrupa Executive Director Mark Brown, in an April 13 interview with ResourceStockDigest, stated that Avrupa has a "great geological team there in Portugal. They've made discoveries before. But the oversight by a group that's actually operating a mine of this kind [OZ Minerals] is also very, very key for us and just adds to the whole intelligence and wisdom of the group over there in deciding where to put drill holes."

In March, the Portuguese Mining Bureau approved a 30-month extension to the Alvito exploration license, covering around 300 square kilometers of prospective ground along the "AlcaƧovas copper-gold trend identified by Avrupa geologists in 2011–12." The company stated that "subsequent field work was successful in identifying potential for significant copper-gold-silver mineralization in known and several new occurrences."

In addition to Alvito, Avrupa has option and joint venture agreements at Alvalade and Covas in Portugal and Slivovo in Kosovo.

Want to read more Gold Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: Avrupa Minerals Ltd. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

( Companies Mentioned: AVU:TSX.V, 8AM:FWB, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17415

Wednesday, April 26, 2017

Stand on Guard for Thee (Canada)

Source: Michael J. Ballanger for The Gold Report   04/26/2017

The tariff the Trump Administration plans to slap on Canadian lumber imports should lead to a further weakening of the Canadian dollar, a move that precious metals expert Michael Ballanger says can only help the bottom line of Canadian gold producers.

Over the past 40 years, the British Columbia lumber business has always taken great glee in plucking the chin hairs out of Uncle Sam's beard by legislating protection for its markets by way of subsidies and tax credits with political parties catering and pandering to the voting workers in an industry that dominates the provincial workforce ranking second only to agriculture.

Each time one of the grey bristles was plucked from that star-spangled beard, the Big Man would flinch and growl and wave his massive arm as if to swat away the irritant but NEVER would Uncle Sam do anything but make noise. Now, with news that the Trump Administration intends to slap a 24% tariff on Canadian lumber exports to the U.S., the first cannonball in the dismantling of NAFTA has sailed across the bows of the Mexican and Canadian frigates moored in the harbor of international trade.

The Canadian dollar has been smoked for a 0.65% haircut Tuesday and that trend is NOT going to end any time soon because of the old adage that "there is never only one cockroach"; these U.S. politicians will have a sitting duck target in their northern neighbors because Canada has absolutely zero leverage in the negotiations. With that, the Americans are bound to graduate from the obvious lumber bogeyman to other things like pipelines and banking and livestock, because once politicians see the popularity meter rising, they will seize upon this protectionist bandwagon like flies to manure.

As this movement gains popularity and as more and more Canadian export industries are revealed as targets by the media-hungry, tweet-crazy American Commander-in-Chief, the lower the Canadian loonie will go and the happier I will be as a shareholder of gold-producing Canadian companies.

Gold 10-Year in Canadian DollarsGold 10-Year in US Dollars

These two charts clearly illustrate how currency fluctuations have benefitted Canadian gold miners with particular emphasis upon those with Canadian mines and operations. They are selling a product sitting within CA$115 of the 2011 high while its U.S. counterpart is around US$639 from the same peak price. Everyone in the Canadian banking business loves a weak Canadian dollar because it invites all manner of foreign investors piling into Canadian assets with the prime recipient being real estate. Forget the impact it has on fruit and vegetables and orange juice, just buy a 1,500 square-foot house for CA$1,000,000 and your capital appreciation will cover the additional cost of living fivefold! Buy now and sell that starter home in six months for $1,400,000 to a Chinese family immigrating from Beijing with CA$10 million granted to them by an associate of the Communist Party with instructions to "own real estate."

However, it IS a tremendous earnings windfall for Canadian miners selling their products in USD while incurring all extraction costs in CAD. Furthermore, when one glances at the chart of the USD Index (shown below), it is painfully clear how the Trump Effect for "Make America Great Again" has now eluded the USD since the New Years Day peak and has been in a downward spiral ever since.

Currency debasement around the globe has created a "race to the bottom" in terms of purchasing power, which translates into monetary inflation of global dimension emanating from every central banker on the planet. Synonymous with this is the urgent call to suppress the precious metals while supporting stocks and bonds in the interest of "national security" in much the same manner that Germany and Japan did during WWII.

The problem with trying to fight the stock market and these innumerable interventions is that one should "never underestimate the replacement power of stocks within an inflationary spiral" or, in this case, a "reflationary spiral." As I have been raging about for at least the last 30 years, the only way I could earnestly short common stocks with absolute confidence would be if there was an implied "guarantee" that government would adhere to a sound money policy where currency debasement was punishable by way of life imprisonment. And as Kyle Bass said in Michael Lewis' "Boomerang," that will happen "when pigs fly out of your a--!"

US Dollar Index

About 11:00 a.m. Tuesday, I tweeted that I had "pinched both nostrils and bought 10,000 JNUG [Direxion Daily Junior Gold Miners Bull 3X ETF] at $4.32 with a stop at $3.98 and a $6.50 target with full knowledge that I could get stopped out before the end of the day. As it turned out, JNUG came off the canvas after a low of $4.26 and closed at $4.55 despite a late-day decline in gold prices.

Since the JNUG trades off the GDXJ [VanEck Vectors Junior Gold Miners ETF], I surmised that the RSI [relative strength index] being at around 30 is as good an entry level as you can get so I took on the JNUG to play the oversold bounce even though MACD [moving average convergence divergence] and histograms look like they need to do a little more work down here.

I am going to buy 30,000 JNUG into this pullback so it could be said that today I took a 1/3 position. I won't necessarily chase the bounce if it turns out that Tuesday was the low but I will add if they take JNUG down under $4.00 mid-week. Of course I will be heavily medicated and barricaded in my office by that point burning Washington Capitals figures dressed up like bankers and firing darts at pictures of our illustrious Prime Minister shaking hands with the Dalai Lama—you know—a NORMAL day for me when the metals are under attack.

GDXJ Chart

I urge all Canadians to batten down the hatches because 76% of our exports go to the U.S. and if Uncle Sam decides to get tough with Canada, there is little the country can do except adapt to the changes. I have to laugh with the Canuck politicians threatening to sue the U.S. because they are violating the free-trade agreement but since that was a contract drawn up ages ago, I offer the immortal words of Ray Kroc, the thief who stole the immortal restaurant chain from the two original McDonald brothers, "Contracts are like hearts; they are meant to be broken." If the Americans decide to use Canada as the poster child for protectionist changes to American market access, there are going to be a great many broken hearts out there and they won't all be in British Columbia.

Originally trained during the inflationary 1970s, Michael Ballanger is a graduate of Saint Louis University where he earned a Bachelor of Science in finance and a Bachelor of Art in marketing before completing post-graduate work at the Wharton School of Finance. With more than 30 years of experience as a junior mining and exploration specialist, as well as a solid background in corporate finance, Ballanger's adherence to the concept of "Hard Assets" allows him to focus the practice on selecting opportunities in the global resource sector with emphasis on the precious metals exploration and development sector. Ballanger takes great pleasure in visiting mineral properties around the globe in the never-ending hunt for early-stage opportunities.

Want to read more Gold Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Statements and opinions expressed are the opinions of Michael Ballanger and not of Streetwise Reports or its officers. Michael Ballanger is wholly responsible for the validity of the statements. Streetwise Reports was not involved in any aspect of the article preparation. Michael Ballanger was not paid by Streetwise Reports LLC for this article. Streetwise Reports was not paid by the author to publish or syndicate this article.
2) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
3) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Charts courtesy of Michael Ballanger.



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17414

Trial Results Set Up DURECT Corp. for 'Exciting Year'

Source: The Life Sciences Report   04/26/2017

Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts.

In an April 23 conference update, analyst David Sherman of LifeSci Capital commented on the results of DURECT Corp.'s (DRRX:NASDAQ) Phase 1b study of DUR-928, noting the compound "was well tolerated overall," that the data support ongoing evaluation of the therapy, and that "investigators speculated on the plausibility of a therapeutic effect due to biomarker reductions at approximately 12 hours following dosing."

In an April 25 Laidlaw & Company research report, analyst Francois Brisebois observed that at its lowest dose, DUR-928 "showed reduction in liver function and injury biomarkers after only 12 hours. Additionally, inflammation markers and mediators such as high sensitivity C-reactive protein (hsCRP) and IL-18, as well as CK18 (cell death biomarker), were reduced in NASH (especially in cirrhotics). The full data set confirmed these findings with a single dose, which is a real positive in our opinion."

The Laidlaw analyst also noted that with the Phase 3 PERSIST trial "of Posimir for post-operative pain expected to read-out by year end-2017, IND [investigational new drug] filings in both liver and kidney programs around mid-2017 and initiation of a Phase 2 trial for DUR-928 in mid-2017 for primary sclerosing cholangitis (PSC), 2017 should be an exciting year for DRRX."

According to a report by Reuters, the market for NASH, also known as nonalcoholic fatty liver disease, "is forecast to be $20 billion to $35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments."

Large pharmas including Pfizer Inc. (PFE:NYSE) and Bristol-Myers Squibb Co. (BMY:NYSE) are looking for candidates for development and marketing, according to the Reuters article, which quotes Morris Birnbaum, chief scientific officer for internal medicine for Pfizer, as saying the company is "actively looking on the outside for opportunities . . .to complement our internal program."

The Reuters article also quoted Len Yaffe of StockDoc Partners, who noted the DURECT drug "looks incredibly promising as it relates to inflammation and fibrosis." Yaffe told the news agency that "investors with tolerance for risk could do well to buy shares in several small-cap and micro-cap companies with promising NASH drugs in early development . . .the payoff could be considerable."

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned are sponsors of Streetwise Reports: DURECT Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: DRRX:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17413

VistaGen's Fast-Acting Antidepressant Targets Multibillion-Dollar Market

Source: The Life Sciences Report   04/26/2017

Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders.

Noting that patients often must wait months to see if existing therapies will provide relief, VistaGen Therapeutics Inc.'s (VTGN:NASDAQ) AV-101 "is part of an emerging class of antidepressant drugs targeting the NMDA receptor for adjunctive treatment of MDD [major depressive disorder] and has the potential for rapid relief of depressive symptoms within days (vs. months)," the Maxim initiation report states.

The March 28 report goes on to note that, "The opportunity in MDD adjunctive therapy (and any depression market segment) is large and, as such, attracts pharma."

Data from a Phase 2 trial for AV-101 as a monotherapy for MDD is due in Q4/17, according to Maxim. The company is also designing a Phase 2 "adjunctive therapy study that is expected to initiate in 2H17," the report stated. Because that study uses "Sequential Parallel Comparison Design," which is part of the Alkermes Plc (ALKS:NASDAQ) "playbook" and has been shown to both minimize placebo effect and increase "trial powering," VistaGen can "conduct a smaller, more rapid, and cost-effective study to achieve proof of concept (POC) data by late 2018."

In the report, Maxim maintains that AV-101 "has the potential to be faster-acting and safer than standard FDA-approved antidepressants." The drug is "similar to ketamine, and acts in the brain through the same glutamatergic AMPA-dependent pathway, rapidly inducing antidepressant effects via a final common pathway."

In addition, "AV-101 has been shown to be safe and well-tolerated in two NIH-funded Phase I safety studies with no ketamine-like side effects," Maxim stated, adding the therapy could also prove efficacious in other central nervous system indications, including "chronic neuropathic pain and epilepsy, as well as neurodegenerative diseases, such as Parkinson's disease and Huntington's disease."

While AV-101 shows promise as a monotherapy, Maxim is bullish on its use as an adjunct therapy while patients wait for other treatments to take effect. "A majority of patients will experience months to years of trial and error to find an effective combination of therapies that alleviate depressive disorders," the report states. "New adjunctive therapies that are in development have a rapid onset of action (days to weeks) can bridge the therapeutic gap especially for patients in crisis. We see this segment alone as a multi-billion dollar opportunity."

While there is some risk because the company is expected to need to raise capital, Maxim states, "With a current valuation of less than $20M we see nominal downside risk to our 12-month target and look instead at the potential for upside if a partner were to step into the opportunity ahead of data while the valuation is depressed."

Maxim has initiated coverage on VistaGen with a Buy rating and a $4 price target. VistaGen is currently trading at around $1.97.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own shares of VistaGen Therapeutics Inc., a company mentioned in this article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: VTGN:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17412

Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials

Source: The Life Sciences Report   04/26/2017

Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials.

Zynerba Pharmaceuticals Inc. (ZYNE:NASDAQ) expects to release data in the third quarter from its Phase 2 STAR (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) trial for ZYN002 in adult refractory focal seizures. In the trial, according to Maxim's March 28 report, the patients "have been randomized to receive 195mg, 390mg, or placebo. The primary end point is median percentage change in seizure frequency over the 12-week treatment period."

"Of 110 patients who have completed the STAR 1 study, 106 patients have enrolled into STAR 2, an open label long-term safety and tolerability study of ZYN002 for up to 52 weeks. After completion of Phase II, the company expects to meet with the FDA to initiate Phase III in the U.S. in 1H18." Maxim stated.

If the STAR 1 results are favorable, Maxim states that it "could count as one of two pivotal trials necessary for approval. . .for focal seizure only, FDA's recent guideline allows for the use of results from the two pivotal trials for children four years and up, requiring only PK and drug interaction study; meaning, a monotherapy trial is not necessary for an indication in children four years and up."

Maxim sees Zynerba as a "tangential play on GW Pharma, with a differentiated mode of delivery (transdermal vs. oral) of the same CBD (cannabidiol). ZYN002 has a better safety and bioavailability profile, and is a synthetic (vs. plant based), which means higher margins and better quality control. Zynerba is also targeting a much larger indication in Epilepsy vs. orphan drug indications for GW Pharma."

Maxim has a 12-month target price on Zynerba of $32. The shares are now trading around $22.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: ZYNE:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17411

Tuesday, April 25, 2017

AudioEye Is Rapidly Making the Internet Accessible to All

Source: Streetwise Reports   04/25/2017

AudioEye's innovative technology, which makes the internet available to people with disabilities, has led to rapid growth for the company.

Up to 15% of people worldwide have a disability that affects their ability to use the internet. Issues include blindness and low vision, hearing impairments and deafness, limited motor control, and learning and cognitive disabilities. AudioEye Inc. (AEYE:OTCQB) has developed the technology to make the internet accessible, and sales are skyrocketing.

AudioEye uses a simple JavaScript that resolves many issues of web accessibility. According the company, it has created a "proprietary and patented technology that automatically and dynamically remediates issues of web accessibility."

The company notes that its technology was developed to assist "organizations in making web content both accessible and compliant in the most effective, expedient, and economical manner." The technology helps companies comply with the Web Content Accessibility Guidelines (WCAG) 2.0 and stay in compliance with the Americans with Disabilities Act.

On April 10, AudioEye announced that in Q1/17, it had secured bookings of more than $1.7 million. Bookings for all of 2016 totaled $1.6 million.

Despite the high bookings in Q1/17, the company says it has a pipeline of more than $5.3 million. Earlier the company had stated that it expected bookings of between $4 million and $6 million in 2017.

Dr. Carr Bettis, executive chairman of AudioEye stated, "The first quarter was a breakout quarter for AudioEye, with record bookings driven by accelerating adoption of our digital accessibility platforms within our targeted industry markets."

AudioEye has been targeting financial services, human resources, government, education and e-commerce, and the company has added 105 new banking clients in the past quarter.

Todd Bankofier, CEO of AudioEye, stated, "Customers are increasingly drawn to AudioEye's unique ability to assess a new customer site through our software driven solutions, then engaging our automated remediation technology to correct between 40-60% of the accessibility issues within a matter of hours. After this initial assessment and remediation, we work closely with customers to bring their sites into full compliance with the Web Content Accessibility Guidelines 2.0 AA standards in 100 days, then monitor their content for the life of the subscription. This ensures AudioEye customers continue to comply with the latest standards and best practices in digital accessibility."

Included on AudioEye's board of directors is Tony Coelho. A former member of the U.S. House of Representatives, Coelho is credited by Congressional colleagues as the author of the Americans with Disabilities Act. He formerly chaired and currently sits on the Board of Directors of the American Association of People with Disabilities.

AudioEye trades on the OTCQB exchange under the ticker AEYE; the company currently has a market cap of about $22.2 million.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own shares of AudioEye Inc., a company mentioned in this article.

( Companies Mentioned: AEYE:OTCQB, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17410